At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACON ACLARION, INC
Trading 09-10 10:09:24 EDT
2.47
+0.04
+1.86%
High2.47Low2.47Vol1.33K
Open2.47D1 Closing2.42Amplitude0.00%
Mkt Cap7.11MTradable Cap6.46MTotal Shares2.88M
T/O3.28KT/O Rate0.05%Tradable Shares2.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as Clarity Trial Site
THOMSON REUTERS  ·  08-20
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as Clarity Trial Site
Aclarion - Anticipates Having Initial Internal Data Readout & Expected Public Disclosure of Early Interim Results in Q4
THOMSON REUTERS  ·  08-20
Aclarion - Anticipates Having Initial Internal Data Readout & Expected Public Disclosure of Early Interim Results in Q4
Aclarion Adds University of Arizona College of Medicine–Phoenix as Clarity Trial Site for Nociscan
Reuters  ·  08-20
Aclarion Adds University of Arizona College of Medicine–Phoenix as Clarity Trial Site for Nociscan
Aclarion Director Amanda M Williams Reports Purchase of 5,857 Common Shares Worth $15,989.61
Reuters  ·  08-19
Aclarion Director Amanda M Williams Reports Purchase of 5,857 Common Shares Worth $15,989.61
Aclarion CEO Brent Ness Reports Purchase of 5,234 Common Shares for $12,093.54
Reuters  ·  08-17
Aclarion CEO Brent Ness Reports Purchase of 5,234 Common Shares for $12,093.54
Aclarion Says USPTO Issues Notice of Allowance for Lumbar Disc MRS Scan-Prescription Patent Application
Reuters  ·  08-12
Aclarion Says USPTO Issues Notice of Allowance for Lumbar Disc MRS Scan-Prescription Patent Application
Aclarion Q2 FY26 Net Loss Narrows 59.27% to $2.75 Million; Revenue Rises 30.5% to $25,208
Reuters  ·  08-06
Aclarion Q2 FY26 Net Loss Narrows 59.27% to $2.75 Million; Revenue Rises 30.5% to $25,208
Aclarion Announces Availability of CEO Shareholder Letter
Reuters  ·  07-29
Aclarion Announces Availability of CEO Shareholder Letter
Aclarion Notifies Availability of Press Release on Nociscan Clinical Use Abstracts
Reuters  ·  07-21
Aclarion Notifies Availability of Press Release on Nociscan Clinical Use Abstracts
Aclarion Launches Market Access Program With PRIA Healthcare
MT Newswires Live  ·  06-09
Aclarion Launches Market Access Program With PRIA Healthcare
BRIEF-Aclarion Stockholders Approve All Proposals At 2026 Annual Meeting
Reuters  ·  06-08
BRIEF-Aclarion Stockholders Approve All Proposals At 2026 Annual Meeting
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
THOMSON REUTERS  ·  06-08
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
Aclarion - Board Says Echo Lake Proposal Significantly Undervalues Company
THOMSON REUTERS  ·  06-08
Aclarion - Board Says Echo Lake Proposal Significantly Undervalues Company
Press Release: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
Dow Jones  ·  06-08
Press Release: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
Press Release: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Dow Jones  ·  06-08
Press Release: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Aclarion holds annual shareholder meeting
Reuters  ·  06-05
Aclarion holds annual shareholder meeting
Aclarion signs agreement with Institute of Neuro Innovation to offer Nociscan in Los Angeles area
Reuters  ·  06-03
Aclarion signs agreement with Institute of Neuro Innovation to offer Nociscan in Los Angeles area
Aclarion says Nociscan study links intradiscal propionic acid to immune-activated back pain subtype
Reuters  ·  06-01
Aclarion says Nociscan study links intradiscal propionic acid to immune-activated back pain subtype
Aclarion Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  05-29
Aclarion Is Maintained at Buy by Ascendiant Capital
Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal
TIPRANKS  ·  05-29
Aclarion to ‘carefully review and evaluate’ Echo Lake’s proposal

Introduction

Company Name.
ACLARION, INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Issue price:
--